Indian Journal of Endocrinology and Metabolism

BRIEF COMMUNICATION
Year
: 2015  |  Volume : 19  |  Issue : 3  |  Page : 426--429

Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions


Sanjay Kalra1, Yashdeep Gupta2, Shiva Patil3 
1 Department of Endocrinology, Bharti Hospital and B.R.I.D.E, Karnal, Haryana, India
2 Department of Medicine, Government Medical College and Hospital, Chandigarh, India
3 Senior Medical Advisor, Boehringer Ingelheim, Mumbai, India

Correspondence Address:
Sanjay Kalra
Executive Editor, Indian J Endocrinology and Metabolism, Bharti Hospital and B.R.I.D.E, Karnal - 132 001, Haryana
India

The sodium-glucose cotransporter 2 (SGLT-2) inhibitors are a novel class of glucose-lowering drugs which act by inhibiting the reabsorption of filtered glucose from the kidneys. Their effect on insulin and glucagon levels has recently been studied but is not fully explained. This communication proposes various hypotheses: A direct effect of SGLT-2 inhibition on the alpha cell receptors, a paracrine or intra-islet mediated effect on alpha cell sensitivity to glucose, and a calorie restriction mimetic action, to explain the impact of these drugs on the insulin glucagon ratio.


How to cite this article:
Kalra S, Gupta Y, Patil S. Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions.Indian J Endocr Metab 2015;19:426-429


How to cite this URL:
Kalra S, Gupta Y, Patil S. Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions. Indian J Endocr Metab [serial online] 2015 [cited 2021 Apr 17 ];19:426-429
Available from: https://www.ijem.in/article.asp?issn=2230-8210;year=2015;volume=19;issue=3;spage=426;epage=429;aulast=Kalra;type=0